Travere Therapeutics, Inc. (TVTX) stock analysis
In our weekly check, Travere Therapeutics, Inc. is graded D (A to F). Of 22 checks on debt, profit, cash flow and trend: 11 pass, warnings: 1, red flags: 10.
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as TVTX.
What our checks show for TVTX
Red flags
- Debt is high against equity (27.28x). That limits room in a downturn.
- The company has an operating loss, so it does not cover the interest bill: interest is paid from cash or new debt.
- Earnings per share fell 29.1% a year over the last 3 years.
- The company is losing money: the net margin is -18.7%.
- Free cash flow is negative (-3.1% of revenue): the business spends more cash than it brings in.
- The price swings a lot: 56.9% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 85% from a peak. Would you have held through that?
- The share count grew by 20.1% in 2 years: each shareholder owns a smaller slice.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- The gross margin fell by 2.4 points, to 94.7%: costs are rising faster than prices.
Strengths
- The net margin rose by 118 points over 5 years, to -18.7%.
- Operating cash flow is 0.31x net profit: the profit arrives as real cash.
- Analysts expect earnings per share to grow about 57% a year over the next years.
- Analysts expect revenue to grow about 42.2% a year over the next years.
- Analysts expect the net margin to improve by 48.2 points from today's -18.7%.
- Revenue grew 81.2% a year over the last 3 years.
Similar companies
IONS · EWTX · COGT · ADPT · DNTH · SRRK
Questions
What grade does Travere Therapeutics, Inc. (TVTX) have?
In our weekly check, Travere Therapeutics, Inc. is graded D (A to F). Of 22 checks on debt, profit, cash flow and trend: 11 pass, warnings: 1, red flags: 10. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of TVTX stock?
This week's biggest flags for Travere Therapeutics, Inc.: High debt, Weak interest cover, Weak EPS growth. In total 11 of 22 checks show a warning or a red flag.
What does Travere Therapeutics, Inc. do?
Travere Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as TVTX.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis